Re.Mo.Te clinical study
Re.Mo.Te was the first European study to assess, with both clinical and organisational objectives, the efficacy of a remote monitoring service (Doctor Plus®) for patients with type 2 diabetes. More specifically, the study’s main objective was to evaluate the use of a home monitoring system (monitoring basic parameters such as weight, glycaemia, blood pressure and lipid panel) for the improvement of glycaemic control (HbA1c) in diabetic patients, compared to routine management by the patient’s GP. In addition to the primary objectives, the study also set other, primarily organisational objectives, such as reducing the number of emergency admissions to A&E and hospitalisations and the number of GP appointments and house visits.
Doctor Plus® for home dialysis patients
In Italy, over 50,000 people have dialysis. Telemonitoring systems offer a number of advantages, such as better clinical control of the patient, verification of prescription compliance and a reduction in admissions to A&E. These advantages formed the foundations of a pilot telemonitoring service for patients receiving peritoneal dialysis at P.O. G.B. Grassi (ASL Roma3) named Doctor Plus®, in which Vree Health Italia participated. The data showed a 29% reduction in A&E admissions. Patients felt better and their quality of life improved. The Vree Health Italia Doctor Plus® system was seen to be able to guarantee prompt control, with a reduction in the number of A&E admissions.
Economic and organisational aspects of chronic patient management models in healthcare settings.
Patients with type 2 diabetes mellitus (T2DM) were included in the home telemonitoring service. Each one was observed for 12 months between 2013 and 2014 and efficacy and costs were compared. The result of this economic analysis showed that the adoption of a telemonitoring service by a diabetic patient of between 45 and 80 years of age, represents a dominating treatment option. As diabetes is a chronic illness, the validity of the results obtained during this study requires further (future) clinical and economic evidence regarding the use of the telemonitoring service in the management of patients with this condition. The results of the analysis conducted by Rome B Local Health Authority were published in the journal AboutPharmaCoEconomics, Economic and organisational aspects of chronic patient management models in healthcare settings, October 2015.
Doctor Plus® for patients with diabetes
In Italy, more than 3 million people have diabetes. A telemonitoring service was set up for diabetic patients treated at A.O. Ospedaliera di Terni, named Doctor Plus®, with the participation of a company (Vree Health) specialising in the implementation of novel organisation systems for healthcare settings, using certified cutting-edge technologies.
A nursing Contact Center was set up and each patient was given a home telemonitoring kit. Between August 2014 and April 2017 (32 months), 82 patients took part, for a total of 85,592 recorded measurements. After 4 months, the number of unscheduled specialist consultations had dropped from 22.8% to 14.04% of cases and the number of A&E admissions for all causes dropped from 15.8% to 14.04% of cases, with no admissions being associated with glycaemia alone. The telemonitoring service is perceived as an innovative service by patients. The data were measured and processed by Vree Health, provider of the Doctor Plus® service.